Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 10Neoplasms 4Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Spinal Cord Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Sarcoma 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms by Site 1Multiple Myeloma 1Meningioma 1Lymphoma, Non-Hodgkin 1Low Grade Serous Ovarian Carcinoma 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Liposarcoma 1Leiomyosarcoma 1Hereditary Sensory and Autonomic Neuropathies 1Hemangiosarcoma 1HR+/HER2- Breast Cancer 1Glioma 1

Interventions

Specimen Handling 8Magnetic Resonance Spectroscopy 7Biopsy 7pembrolizumab 6Doxorubicin 6Cyclophosphamide 6X-Rays 4Radiation 4Phantoms, Imaging 4Radiotherapy 3Nuclear Medicine Department, Hospital 3Irinotecan 3Ifosfamide 3ulixertinib 2tipifarnib 2selpercatinib 2pazopanib 2palbociclib 2liposomal doxorubicin 2ivosidenib 2fludarabine 2ensartinib 2atezolizumab 2Temozolomide 2Surveys and Questionnaires 2Gemcitabine 2Fluorodeoxyglucose F18 2Carboplatin 2Bevacizumab 2trifluridine tipiracil drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × abemaciclib × 30 days × Clear all
NCT06498648 2026-05-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
74 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡